Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Find information and resources for current and returning patients.
Learn about clinical trials at MD Anderson and search our database for open studies.
The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Your gift will help support our mission to end cancer and make a difference in the lives of our patients.
Our personalized portal helps you refer your patients and communicate with their MD Anderson care team.
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.
Choose from 12 allied health programs at School of Health Professions.
View open postdoctoral and other research trainee positions.
Learn about our graduate medical education residency and fellowship opportunities.
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
MD Anderson Cancer Center News Release
In New ‘Cool 100,’ Mag Counts Down Houston’s Top Movers, Shakers and Makers Opens a new window
Houston City Book
11/17/2022 to 11/18/2022
2022 Leading Edge of Cancer Research Symposium
Annual Meeting 2022: The New Frontier of Immunotherapy in Lung Cancer - Boosting the Immune Response Before Surgery. Opens a new window
Cancer Research Catalyst, The Official Blog of the American Association for Cancer Research
Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Opens a new window
New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy Opens a new window
ASCO Post Interview
AACR: Combination immunotherapy treatment effective before lung cancer surgery
MD Anderson Cancer Center News Release
Neoadjuvant immunotherapy can produce nodal immune flair in lung cancer. -- Cascone T and Sepesi B. Opens a new window
Newswise. MD Anderson Research Highlights for August 25, 2021.
Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC Opens a new window
Oncology Times, Volume:43 Number 12, page 1,11 – 11
Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer Opens a new window
ESMO Oncology News
Study reveals promising, less toxic treatments for patients with lung cancer. Opens a new window
Conquer Cancer. The ASCO Foundation News.
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer -- Cascone T and Sepesi B.
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting. Highlights include positive clinical data from combination therapies in patients with melanoma and lung cancer - Cascone T and Sepesi B.
MD Anderson Newsroom
Remaining Challenges With Perioperative Immunotherapy in NSCLC. Opens a new window
Toxicity Of Nivolumab and Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting Opens a new window
Nivo/ipi shrinks early NSCLC before surgery Opens a new window
MedEdge Conference Coverage
Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung Cancer Opens a new window
Cancer Network Interview
Neoadjuvant Nivolumab/Ipilimumab Shows Promise in Resectable NSCLC Opens a new window
ASCO Daily News
ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers Opens a new window
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab Opens a new window
Priming Immune System Prior to Surgery May Improve Outcomes Opens a new window
Oncology Times, August 5, 2018 - Volume 40 - Issue 15 - p 22,31.
Spotlight: What I Do As A Cancer Researcher Opens a new window